Investors


We are proud to have some of the leading Life Sciences and Healthcare investors backing TopiVert:

SV Health Investors

SV Health Investors (‘SV’) is a leading international life sciences venture capital firm. SV’s affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.

The SV team manages six private venture capital funds with approximately $2.1 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalise on an expanding opportunity in biotech, medical devices and healthcare services. SV has offices in Boston, London and San Francisco.

Touchstone Innovations

Touchstone Innovations plc (formerly Imperial Innovations Group plc or just “Innovations”) creates, builds and invests in pioneering technology companies and licensing opportunities developed from outstanding scientific research from the ‘Golden Triangle’, the geographical region broadly bounded by London, Cambridge and Oxford.

Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through protecting and licensing out intellectual property (through its Technology Transfer subsidiary, Imperial Innovations Limited), by leading the formation of new companies, by recruiting high calibre management teams and by providing investment and encouraging co-investment. Innovations remains an active investor over the life of its portfolio companies, with the majority of Innovations’ investment going into businesses in which it is already a shareholder.

Between Innovations’ admission to AIM (August 2006) and 31 January 2017, Innovations has invested a total of £335.7 million across its portfolio companies, which have collectively raised investment of £1.5 billion.

Johnson & Johnson Innovation - JJDC, Inc. (JJDC)

JJDC is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, it determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.

JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Neomed Management AS (Neomed)

NeoMed is a Jersey headquartered investment firm, exclusively focused on investments in the healthcare industry. Founded in 1997, NeoMed has established five funds to date.

It invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries.

NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, it has successfully invested in more than 40 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.

From offices in Jersey, Switzerland and Norway, NeoMed’s experienced investment team works closely with entrepreneurs and a broader industry network to support the growth of its portfolio companies.